THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...

Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 4, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...

Amgen AMGN stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart ...

It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Some analysts expect the market could be worth $ ...

Many therapies aren't nearly as successful as hoped. Biotech giant Amgen (NASDAQ: AMGN) has had a harsh reminder of that reality in recent years. Some of its most recent brand-new launches ...

Since its founding in 1980, Amgen has devoted itself to fostering a culture of innovation. The company has routinely spent between 16% and 19% of its total revenue on research and development for ...